%0 Journal Article
%T A neuraminidase potency assay for quantitative assessment of neuraminidase in influenza vaccines
%A David F. Miller
%A Jacob H. Gillis
%A Kathy L. Rowlen
%A Katie M. Bueter
%A Laura R. Kuck
%A Rose T. Byrne-Nash
%J Archive of "NPJ Vaccines".
%D 2019
%R 10.1038/s41541-019-0099-3
%X VaxArray Influenza Seasonal Neuraminidase Potency Assay (VXI-sNA). a Illustration of a VXI-sNA microarray slide containing 16 identical microarrays in 16 wells. b Schematic of the VXI-sNA array layout of subtype-specific antibodies to N1, N2 subtypes and B-NA. Two different monoclonal antibodies (mAbs) are printed for each subtype and distinguished from one another using (i) or (ii) labeling. The array contains nine replicate spots (~200£¿¦Ìm in diameter) of each monoclonal antibody. c Immunoassay schematic. d Qualitative assessment of VXI-sNA capture mAbs for detection of a panel of recent vaccine strains produced across multiple production platforms with a blue box and checkmark to indicate mAb detection of the listed antigen. Detection was defined as 3¡Á the background intensity. e Signal intensities for each VXI-sNA capture mAb against a panel of historical FluZone vaccines from 2004 to 2012. White/empty boxes indicate signal intensity below the 3¡Á background intensity cutoff, yellow indicates signal intensity between 3¡Á and 20¡Á background intensity, green indicates between 20¡Á¨C40¡Á background, and blue indicates between 40¡Á and fluorescence saturatio
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342948/